HNSBF News and Press, Hansa Biopharma AB From 07/18/19

Stock Information

Company Name:	Hansa Biopharma AB
Stock Symbol:	HNSBF
Market:	OTC

HNSBF HNSBF Quote HNSBF Short HNSBF News HNSBF Articles HNSBF Message Board

Get HNSBF Alerts

News, Short Squeeze, Breakout and More Instantly...

Email Address

HNSBF - Hansa Biopharma AB reports Q2 results

Hansa Biopharma AB ( OTC:HNSBF ): Q2 GAAP EPS of -SEK2.06. More news on: Hansa Biopharma AB (publ), Earnings news and commentary, Read more ...

HNSBF - Hansa Biopharma Interim Report January-June 2019

MALMÖ, Sweden , July 18, 2019 /PRNewswire/ -- Imlifidase benefits highlighted in recent ATC presentations. Expansion outside transplantation with initiation of study in Guillain-Barré Syndrome (GBS) continues. Highlights for the second quarter 2019 - At the 2019 American...

HNSBF - Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls

LUND, Sweden , June 7, 2019 /PRNewswire/ -- Hansa Biopharma AB ("Hansa") (NASDAQ Stockholm: HNSA ), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that IDEFIRIXTM (imlifidase), the company's novel IgG-degrading enzyme, was highlighted in ...

HNSBF - Hansa Biopharma to Participate in UBS Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference in New York City

LUND, Sweden , May 13, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences...

HNSBF - ClearBridge Small Cap Value Strategy Portfolio Manager Commentary Q1 2019